Harmony Biosciences Holdings, Inc. reiterated revenue guidance for the year 2024. For the period, the company expects net product revenue of $700 million to $720 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
31.48 USD | +1.29% |
|
+9.27% | -2.54% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.54% | 1.79B | |
+55.95% | 819B | |
+43.62% | 638B | |
-6.98% | 351B | |
+19.08% | 329B | |
+9.05% | 298B | |
+16.30% | 242B | |
+2.41% | 225B | |
+12.47% | 217B | |
+8.91% | 168B |
- Stock Market
- Equities
- HRMY Stock
- News Harmony Biosciences Holdings, Inc.
- Harmony Biosciences Holdings, Inc. Reiterates Revenue Guidance for the Year 2024